-
2023-505616-38-00
4
2024-09-04
Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (
-
2024-510917-14-00
5
2024-09-03
Angelman Syndrome
-
2023-508162-15-00
5
2024-07-12
Chronic HF and comorbid impairment of kidney function who had a recent
-
2023-504962-52-00
5
2024-07-10
Triple negative breast cancer.
-
2023-510213-25-01
6
2024-07-08
Takotsubo Syndrome (TT) is an acute cardiac condition
-
2023-508158-24-00
4
2024-06-25
Moderately to Severely Active Crohn’s Disease
-
2022-501697-19-01
5
2024-06-18
Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leuke
-
2023-505436-35-00
5
2024-06-03
Untreated FLIPI 2-5 Follicular Lymphoma
-
2022-502092-33-00
4
2024-05-31
Extensive-disease small cell lung cancer and high SLFN11-expression
-
2023-503631-18-01
5
2024-05-20
Nervous system diseases
-
2023-504151-27-00
5
2024-05-09
Psychosis associated with Alzheimer’s Disease
-
2023-503208-94-00
6
2024-04-04
Prostate cancer
-
2023-504323-25-01
5
2024-03-19
breast cancer
-
2023-505141-48-00
5
2024-03-07
Fibrosis
-
2023-504835-42-00
4
2024-02-29
Heart Failure (Heart Failure with Reduced Ejection Fraction)
-
2023-505251-43-00
5
2024-02-28
Primary Biliary Cholangitis
-
2023-504863-17-00
5
2024-02-21
1. Lupus Erythematosus, Cutaneous, Subacute
2. Chronic Cutaneous Lupus
-
2022-502113-28-00
5
2024-02-01
Follicular lymphoma
-
2023-503462-23-00
5
2023-12-28
Lung transplant rejection
-
2023-505426-34-01
6
2023-12-18
chronic rhinosinusitis (CRS)
-
2022-502157-33-00
7
2023-09-18
B-Cell Malignancies
-
2022-501831-18-00
4
2023-09-13
Patients with hematologic malignancies and undergoing allogenic hemato
-
2024-513562-19-00
5
2023-08-30
End-Stage Kidney Disease
-
2022-501943-34-00
5
2023-06-27
Alpha-1 Antitrypsin Deficiency-Associated Liver Disease